Increasing efforts are underway to investigate PARP inhibitors as a viable treatment option for advanced and metastatic melanoma, both as monotherapy and in combination with other agents such as immune checkpoint inhibitors and BRAF/MEK inhibitors. The gene discussed is PARP1; the disease is metastatic melanoma.